Gail Boxer Marcus Sells 2,496 Shares of Natera, Inc. (NASDAQ:NTRA) Stock

Key Points

• Gail Boxer Marcus, a director at Natera, Inc., sold 2,496 shares on August 1st for a total of $332,392.32, reducing her ownership by 30.22%.
• Natera's stock is currently valued at $140.12 with a market capitalization of $19.13 billion, and shows significant volatility with a beta of 1.76.
• Analysts maintain a consensus rating of "Moderate Buy" for Natera, with target prices ranging from $170.00 to $218.00, indicating expectations for future growth.

Natera, Inc. (NASDAQ:NTRA - Get Free Report) Director Gail Boxer Marcus sold 2,496 shares of the stock in a transaction on Friday, August 1st. The shares were sold at an average price of $133.17, for a total value of $332,392.32. Following the completion of the transaction, the director directly owned 5,763 shares of the company's stock, valued at approximately $767,458.71. This represents a 30.22% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Gail Boxer Marcus also recently made the following trade(s):

• On Tuesday, July 1st, Gail Boxer Marcus sold 4,299 shares of Natera stock. The stock was sold at an average price of $167.36, for a total value of $719,480.64.
• On Tuesday, June 10th, Gail Boxer Marcus sold 4,000 shares of Natera stock. The shares were sold at an average price of $164.44, for a total value of $657,760.00.

Natera Stock Performance

Shares of NASDAQ:NTRA traded up $3.55 during midday trading on Tuesday, hitting $140.12. The company's stock had a trading volume of 2,254,383 shares, compared to its average volume of 1,290,655. The stock has a market capitalization of $19.13 billion, a price-to-earnings ratio of -95.32 and a beta of 1.76. The stock's 50 day simple moving average is $156.49 and its 200 day simple moving average is $155.43. Natera, Inc. has a fifty-two week low of $97.24 and a fifty-two week high of $183.00.

Natera (NASDAQ:NTRA - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The medical research company reported ($0.50) EPS for the quarter, topping analysts' consensus estimates of ($0.59) by $0.09. Natera had a negative return on equity of 18.29% and a negative net margin of 10.36%. The company had revenue of $501.83 million during the quarter, compared to the consensus estimate of $446.68 million. During the same quarter last year, the company earned ($0.56) EPS. The company's quarterly revenue was up 36.5% on a year-over-year basis. As a group, analysts anticipate that Natera, Inc. will post -1.49 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on NTRA. UBS Group increased their price objective on Natera from $211.00 to $218.00 and gave the company a "buy" rating in a report on Friday, May 9th. Piper Sandler upped their target price on Natera from $205.00 to $210.00 and gave the company an "overweight" rating in a research report on Thursday, May 15th. Wall Street Zen cut Natera from a "hold" rating to a "sell" rating in a research report on Saturday, May 17th. Evercore ISI raised Natera to a "strong-buy" rating and set a $170.00 target price for the company in a research report on Monday, July 28th. Finally, Barclays upped their target price on Natera from $160.00 to $190.00 and gave the company an "overweight" rating in a research report on Friday, May 9th. One investment analyst has rated the stock with a sell rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $183.76.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of NTRA. Guided Capital Wealth Management LLC increased its holdings in shares of Natera by 0.5% during the second quarter. Guided Capital Wealth Management LLC now owns 13,135 shares of the medical research company's stock worth $2,219,000 after purchasing an additional 66 shares during the period. Fulton Bank N.A. increased its holdings in shares of Natera by 2.0% during the first quarter. Fulton Bank N.A. now owns 3,652 shares of the medical research company's stock worth $516,000 after purchasing an additional 71 shares during the period. Wedmont Private Capital increased its holdings in shares of Natera by 4.9% during the second quarter. Wedmont Private Capital now owns 1,580 shares of the medical research company's stock worth $256,000 after purchasing an additional 74 shares during the period. Compound Planning Inc. raised its position in Natera by 4.2% during the first quarter. Compound Planning Inc. now owns 1,914 shares of the medical research company's stock valued at $271,000 after purchasing an additional 78 shares in the last quarter. Finally, QRG Capital Management Inc. raised its position in Natera by 1.5% during the first quarter. QRG Capital Management Inc. now owns 5,417 shares of the medical research company's stock valued at $766,000 after purchasing an additional 81 shares in the last quarter. 99.90% of the stock is owned by institutional investors and hedge funds.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.